Pemshil 100mg Injection

Pemshil 100mg Injection

Prescription requiredRx Required

Salt Composition: Pemetrexed (100mg)

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

1 pcs

About The Product

Used in the treatment of non-small cell lung cancer and malignant pleural mesothelioma.

Description

Pemshil 100mg Injection is an anticancer prescription based medication which is used to treat non small cell lung cancer and malignant pleural mesothelioma. Its contains an active ingredient is Pemetrexed in (100mg) concentration.

They belong to the drug class of antifolate antineoplastic agents that is works by blocking certain enzymes for cancer cell growth and DNA replication therefore, slows tumor growth in the body. The injection is usually administered by a healthcare professional in a hospital as a part of a chemotherapy regimen.


Uses

Treat non small cell lung cancer and malignant pleural mesothelioma.


Side Effects

Patient experience acute or mild symptoms after using Pemshil 100mg Injection. Visit the doctor immediately if any of these persist:

  • Nausea
  • Redness
  • Loss of appetite
  • Reduced hemoglobin level
  • Increased skin pigmentation
  • Watery and inflamed eyes
  • Fever
  • Muscle weakness
  • Dehydration
  • Constipation
  • Skin rash
  • Hair loss
  • Blood infection
  • Severe allergic reaction
  • Breathlessness
  • Reduced white blood cells
  • Kidney failure

How To Use

  • Pemshil 100 mg Injection should be used only under the supervision and prescription of a qualified doctor.
  • The medicine is administered intravenously (into a vein) under medical care or a trained healthcare professional.
  • The injection is usually given as part of chemotherapy treatment, typically once every 3 weeks.
  • Patients are advised not to self-administer the medication woithout discuss with the doctor.

How It Works

  • Pemshil 100mg Injection contains salt composition of Pemetrexed which blocks a specific enzyme that is responsible in the growth of cancer cells in the body.
  • Thereby, it slows tumor growth and stops the cancer cells from spreading to other body parts.
  • The injection combined with other chemotherapy medicines for improved outcomes. It supports long term disease management in certain cancer cases.

Safety Advice

Alcohol
Alcohol is strictly prohibited while taking Pemshil 100mg Injection as this may interrupt with the treatment. Patients should discuss with their doctor for any queries or concerns before or during the treatment.
Pregnancy
Pemshil 100mg Injection should be taken during pregnancy if it is correctly prescribed under doctor guidance.
Breast Feeding
Women who breastfeed their child should consult a healthcare expert as Pemshil 100mg Injection may harm the baby in various ways. It is advisable to consult a doctor before starting the treatment to ensure it is safe and suitable for your condition.
Driving
Pemshil 100mg Injection can cause dizziness, fatigue, or weakness, which may affect your ability to drive or operate machinery. Avoid such activities if you are experiencing these symptoms.
Kidney
Patients with kidney disease should take precaution while using Pemshil 100mg Injection because medicine can interfere with the kidney functions.
Liver
Patient with liver problems should inform their doctor while taking Pemshil 100mg Injection as dose adjustment should be needed.

FAQs

It is not known whether Pemshil 100mg Injection is safe for use in children.

Therefore, a doctor’s consultation is recommended, do not self-administer the medication.

References

  • Rollins, K. D., & Lindley, C. (2005). Pemetrexed: a multitargeted antifolate. Clinical therapeutics, 27(9), 1343-1382.
  • Chattopadhyay, S., Moran, R. G., & Goldman, I. D. (2007). Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Molecular cancer therapeutics, 6(2), 404-417.
  • Adjei, A. A. (2004). Pharmacology and mechanism of action of pemetrexed. Clinical lung cancer, 5, S51-S55.
  • Adjei, A. A. (2003). Pemetrexed (Alimta®): a novel multitargeted antifolate agent. Expert review of anticancer therapy, 3(2), 145-156.
  • Hazarika, M., White, R. M., Johnson, J. R., & Pazdur, R. (2004). FDA drug approval summaries: pemetrexed (Alimta®). The oncologist, 9(5), 482-488.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026